证券代码：000950 证券简称：重药控股 重药控股股份有限公司投资者关系活动记录表 编号：2025-004 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动类 | □媒体采访 业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | | 线上参与公司 年度业绩说明会的投资者 2024 上市公司接待人员： | | | 董事长 袁泉 | | 活动参与人员 | 独立董事 刘胜强 | | | 财务总监、董事会秘书 邱天 | | | 证券事务代表 赵婧 | | 时间 | 年 月 日下午 2025 5 6 15:00-16:00 | | 地点 | 价值在线（www.ir-online.cn） | | 形式 | 网络互动方式 | | | 1、重药控股如何促进提高国有资产的保值增值，切实回报 | | | 投资者。 重药控股上市有 年多了，股价长时间低于净资产值， 6 | | | 至今股价也低于 2017 年重药上市时的配售发行价（5.93 元/股）， | | | 令战略投资者和普通投资者在 年多时间里，长期处 ...

Core Viewpoint - Chongqing Pharmaceutical Holdings (重药控股) faces regulatory scrutiny due to inaccuracies in its 2023 financial reporting, leading to a decline in stock price and concerns over potential earnings manipulation [2][3]. Financial Performance - In 2023, Chongqing Pharmaceutical Holdings reported revenue of approximately 801.2 billion yuan, an increase of 18.12% year-on-year, while net profit decreased by 31.22% to about 6.55 billion yuan [3]. - The company's cash flow from operating activities showed a significant increase of 77.92%, reaching approximately 5.09 billion yuan [3]. - The company anticipates a decline in net profit for 2024, projected between 290 million and 390 million yuan, representing a year-on-year decrease of 40.45% to 55.72% [3]. Business Operations - The company primarily engages in pharmaceutical commerce, logistics, and industrial research, with a core focus on pure sales business, supplying pharmaceuticals and medical devices directly to hospitals and medical institutions [2]. - Chongqing Pharmaceutical Holdings has over 7,800 secondary and above pure sales customers, with pure sales accounting for approximately 79.37% of total sales, amounting to 635.94 billion yuan [3]. Regulatory Actions - The Chongqing Securities Regulatory Bureau issued an administrative regulatory measure against the company, citing issues such as improper revenue recognition and lack of commercial substance in certain transactions [2]. - The company's chairman, general manager, and financial director have been subjected to regulatory discussions as part of the measures taken [2]. Ownership Changes - In January 2023, the actual controller of Chongqing Pharmaceutical Holdings changed from the Chongqing State-owned Assets Supervision and Administration Commission to the State-owned Assets Supervision and Administration Commission of the State Council [4]. - The change in control was due to the transfer of 2% equity from Chongqing Chemical Medicine to China General Technology Group [5].